

IN THE CLAIMS:

1. (Currently amended) A composition comprising at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin, said at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin having

a mean molecular weight in the range ~~from~~ of 1500 to 3000 daltons;

an anti-Xa activity in the range ~~from~~ of 94 125 to 150 IU/mg;

an anti-IIa activity in the range of up to 10 IU/mg; and

an anti-Xa activity/anti-IIa activity ratio greater than 10:1.
2. (Currently amended) A composition comprising at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin in which the alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has 2 to 26 saccharide units, an anti-Xa activity in the range from of 94 125 to 150 IU/mg and has a 4,5-unsaturated glucuronic acid 2-O-sulphate unit at at least one end.
3. (Currently amended) A composition according to claim 1 in which the alkali or alkaline-earth metal salt of at least one sulphated ~~polysaccharide~~ polysaccharide of heparin has 2 to 26 saccharide units and has a 4,5-unsaturated glucuronic acid 2-O-sulphate unit at at least one end.
4. (Cancelled)
5. (Original) A composition according to claim 2 having a mean molecular weight in the range of 2000 to 3000 daltons.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

6. (Original) A composition according to claim 2 having anti-Xa activity in the range of 140 to 150 IU/mg and a mean molecular weight in the range of 2000 to 3000 daltons.

7. (Original) A composition according to claim 2, in which the at least one alkali or alkaline-earth metal salt is a sodium, potassium, calcium or magnesium salt.

8. (Original) A composition according to claim 2, having an anti-IIa activity in the range of up to 5 IU/mg.

9. (Original) A composition according to claim 2, having an anti-Xa activity:anti-IIa activity ratio greater than 25.

10. (Previously amended) The method of preparing at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin comprising:

depolymerizing a quarternary ammonium salt of the benzyl ester of heparin in an organic medium with a base with a pKa greater than 20;

converting the quarternary ammonium salt of the benzyl ester of the depolymerized heparin to a sodium salt;

saponifying the ester; and

optionally purifying the product;


wherein said base is 1,5,7 triazabicyclo-[4.4.0]-dec-5-ene, 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diaza-phosphorine, a guanidine base, or a phosphazene base.

11. (Original) The method according to claim 10, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has a mean molecular weight in the range of 1500 to 3000 daltons.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


12. (Original) The method according to claim 10, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has an anti-Xa activity in the range of 94 to 150 IU/mg.
13. (Original) The method according to claim 10, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has an anti-IIa activity in the range of up to 10 IU/mg.
14. (Original) The method according to claim 10, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has an anti-Xa activity:anti-IIa activity ratio greater than 10:1.
15. (Original) The method according to claim 10, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin comprises 2 to 26 saccharide units and has a 4,5-unsaturated glucuronic acid 2-O-sulphate unit at at least one end.
16. (Original) The method according to claim 10, in which the quaternary ammonium salt of the benzyl ester of heparin is a benzethonium, cetylpyridinium, or cetyltrimethylammonium salt.
17. (Cancelled)
18. (Previously amended) The method according to claim 10, in which the base of guanidine comprises:



where R_1 is hydrogen or alkyl, and where R_2 , R_3 , R_4 , and R_5 , which are identical or different, and each is a C_1 - C_6 alkyl.

19. (Original) The method according to claim 18, where R_1 is hydrogen, and R_2 , R_3 , R_4 , and R_5 are each methyl.

20. (Previously amended) The method according to claim 10, in which the base of phosphazene comprises:



where R_1 to R_7 are identical or different, and each is a C_1 - C_6 alkyl.

21. (Original) The method according to claim 10, in which the mol ratio of the base with a pK_a greater than 20 to the quaternary ammonium salt of the benzyl ester of heparin ranges from 0.2:1 to 5:1.

22. (Original) The method according to claim 10, in which the degree of esterification of the quaternary ammonium salt of the benzyl ester of heparin ranges from 50 to 100%.

23. (Original) The method according to claim 10, in which the quaternary ammonium salt of the benzyl ester of depolymerized heparin is converted to a sodium salt by treating the reaction medium with an alcoholic solution of sodium acetate.

24. (Original) The method according to claim 10, in which the saponification is carried out by an alkali metal hydroxide.

25. (Original) The method according to claim 10, in which the purification is carried out by hydrogen peroxide.
26. (Currently amended) The method of preparing at least one alkali or alkaline-earth metal salt of at least one sulphated ~~polysaccharide~~ polysaccharide of heparin comprising:
- depolymerizing a quaternary ammonium salt of the benzyl ester of heparin in an organic medium with sodium imidazolate;
 - converting the quaternary ammonium salt of the benzyl ester of the depolymerized heparin to a sodium salt;
 - saponifying the ester; and
 - optionally purifying the product.
27. (Original) The method according to claim 26, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has a mean molecular weight in the range from 1500 to 3000 daltons.
28. (Original) The method according to claim 26, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has an anti-Xa activity in the range from 94 to 150 IU/mg.
29. (Original) The method according to claim 26, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has an anti-IIa activity in the range of up to 10 IU/mg.
30. (Original) The method according to claim 26, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin has an anti-Xa activity:anti-IIa activity ratio greater than 10:1.

31. (Original) The method according to claim 26, in which the at least one alkali or alkaline-earth metal salt of at least one sulphated polysaccharide of heparin comprises 2 to 26 saccharide units and has a 4,5-unsaturated glucuronic acid 2-O-sulphate unit at at least one end.
32. (Original) The method according to claim 26, in which the quaternary ammonium salt of the benzyl ester of heparin is a benzethonium, cetylpyridinium, or cetyltrimethylammonium salt.
33. (Original) The method according to claim 26, in which the mol ratio of the sodium imidazolate to the quaternary ammonium salt of the benzyl ester of heparin ranges from 0.2:1 to 5:1.
34. (Original) The method according to claim 26, in which the degree of esterification of the quaternary ammonium salt of the benzyl ester of heparin ranges from 50 to 100%.
35. (Original) The method according to claim 26, in which the quaternary ammonium salt of the benzyl ester of depolymerized heparin is converted to a sodium salt by treating the reaction medium with an alcoholic solution of sodium acetate.
36. (Original) The method according to claim 26, in which the saponification is carried out by an alkali metal hydroxide.
37. (Original) The method according to claim 26, in which the purification is carried out by hydrogen peroxide.
38. (Original) A method of treating venous thrombosis in a patient in need of such treatment, comprising administering to the patient a composition as claimed in claim 2, in an amount efficacious for the treatment of venous thrombosis.

39. (Original) A method of treating venous thrombosis in a patient in need of such treatment, comprising administering to the patient a composition prepared according to the method as claimed in claim 10, in an amount efficacious for the treatment of venous thrombosis.

40. (Original) A method of treating venous thrombosis in a patient in need of such treatment, comprising administering to the patient a composition prepared according to the method as claimed in claim 26, in an amount efficacious for the treatment of venous thrombosis.

41. (Original) A method of treating arterial thrombotic accidents in a patient in need of such treatment, comprising administering to the patient a composition as claimed in claim 2, in an amount efficacious for the treatment of arterial thrombotic accidents.

42. (Original) A method of treating arterial thrombotic accidents in a patient in need of such treatment, comprising administering to the patient a composition prepared according to the method as claimed in claim 10, in an amount efficacious for the treatment of arterial thrombotic accidents.

43. (Original) A method of treating arterial thrombotic accidents in a patient in need of such treatment, comprising administering to the patient a composition prepared according to the method as claimed in claim 26, in an amount efficacious for the treatment of arterial thrombotic accidents.

44. (Previously amended) A method of treating arterial thrombotic accidents or venous thrombosis in a patient in need of such treatment comprising the administration of a solution of a pharmaceutical composition by the subcutaneous, intramuscular,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

intravenous, or pulmonary route, in which a composition according to claim 2 is an active ingredient present in an amount efficacious for such treatment.

45. (Previously amended) A method of treating arterial thrombotic accidents or venous thrombosis in a patient in need of such treatment comprising the administration of a solution of a pharmaceutical composition by the subcutaneous, intramuscular, intravenous, or pulmonary route, in which a composition produced by the method according to claim 10 is an active ingredient present in an amount efficacious for such treatment.

46. (Previously amended) A method of treating arterial thrombotic accidents or venous thrombosis in a patient in need of such treatment comprising the administration of a solution of a pharmaceutical composition by the subcutaneous, intramuscular, intravenous, or pulmonary route, in which a composition produced by the method according to claim 26 is an active ingredient present in an amount efficacious for such treatment.

47. through 55. (Cancelled)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com